细胞外囊泡:在炎症性肠道疾病中的新潜在治疗剂
Irene Mignini1, Giulia Piccirilli1, Fabrizio Termite1
1CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy.
Cells
|January 11, 2024
概括
细胞外囊泡 (EVs) 显示出治疗炎症性肠病 (IBD) 的前景. 本综述探讨了来自各种细胞的EV如何可能改善性结肠炎和克罗恩氏病.
科学领域:
- 胃肠道学和免疫学
- 细胞生物学和分子医学
- 药物发现和开发 药物发现和开发
背景情况:
- 炎症性肠道疾病 (IBD),包括性结肠炎和克罗恩病,在中度至重度的病例中,治疗反应不佳.
- 确定新的治疗点对于改善IBD管理至关重要.
- 细胞外囊泡 (EVs) 正在成为细胞间通信的关键参与者,并显示出IBD病原和治疗的潜力.
研究的目的:
- 审查目前关于细胞外囊泡 (EVs) 在炎症性肠病 (IBD) 的治疗潜力的证据.
- 分析来自不同细胞来源的EVs的特性,用于IBD治疗.
- 探索EVs可以改善性结肠炎和克罗恩病的肠炎的机制.
主要方法:
- 在IBD中对EV进行临床前研究的全面文献搜索.
- 分析电动汽车特征 (例如,蜂源,货物).
- 在IBD模型中评估治疗效果的拟议作用机制.
主要成果:
- 临床前数据表明,EVs在IBD病原和治疗中发挥作用.
- 来自各种细胞类型的EV表现出治疗潜力.
- 机制包括调节肠道炎症环境.
结论:
- 细胞外囊泡代表了炎症性肠道疾病的有前途的治疗策略.
- 对细胞特异性EV及其机制的进一步研究有必要进行临床应用.
- 基于EV的疗法可以为治疗性结肠炎和克罗恩病提供一种新的方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Intralumenal Vesicles and Multivesicular Bodies
3.5K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.5K
Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142


